Acta Oncologica (May 2024)

Treatment-related mortality among children with cancer in Denmark during 2001-2021

  • Marie C.L. Sørensen,
  • Mie M. Andersen,
  • Klaus Rostgaard,
  • Kjeld Schmiegelow,
  • Torben S. Mikkelsen,
  • Peder S. Wehner,
  • Marianne Olsen,
  • Signe H. Søegaard,
  • Lisa L. Hjalgrim

DOI
https://doi.org/10.2340/1651-226X.2024.27731
Journal volume & issue
Vol. 63, no. 1

Abstract

Read online

Background: Survival of children with cancer has markedly improved over recent decades, largely due to intensified treatment regimes. The intensive treatment may, however, result in fatal complications. In this retrospective cohort study, we assessed temporal variation in the incidence of treatment-related death and associated risk factors among children diagnosed with cancer in Denmark during 2001–2021. Method: Among all children diagnosed with first incident cancer before age 15 years recorded in the Danish Childhood Cancer Register (n = 3,255), we estimated cumulative incidence of treatment-related death (death in the absence of progressive cancer) within 5 years from diagnosis using Aalen–Johansen estimators and assessed associated risk factors using Cox regression. Results: Among all 3,255 children with cancer, 93 (20% of all 459 deaths) died from treatment. Of these treatment-related deaths, 39 (42%) occurred within 3 months of diagnosis. The 5-year cumulative incidences of treatment-related death were 3.3% during 2001–2010 and 2.5% during 2011–2021 (p = 0.20). During 2011–2021, treatment-related deaths accounted for more than half of all deaths among children with haematological cancers. Risk factors varied according to cancer group and included female sex, age below 1 year at diagnosis, disease relapse, stem cell transplantation, central nervous system involvement, and metastasis at diagnosis. Interpretation: Despite increasing treatment intensities, the incidence of treatment-related death has remained stable during the past 20 years in Denmark. Still, clinical attention is warranted to prevent treatment-related deaths, particularly among children with haematological cancers. Patient characteristics associated with increased treatment-related death risk support patient-specific treatment approaches to avoid these fatalities.

Keywords